Select Publications
Journal articles
2023, 'Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain', Clinical and Experimental Dermatology, 48, pp. 984 - 990, http://dx.doi.org/10.1093/ced/llad182
,2023, 'Reply to Tilotta and Bongiorno: Considering the role of resident cutaneous memory T-cell suppression in providing durable atopic dermatitis remission', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1173 - e1174, http://dx.doi.org/10.1111/jdv.19179
,2023, 'The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV-positive individuals: A real-world cohort study', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1659 - 1663, http://dx.doi.org/10.1111/jdv.19020
,2023, 'Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study', Journal of the American Academy of Dermatology, 89, pp. 137 - 138, http://dx.doi.org/10.1016/j.jaad.2022.12.056
,2023, 'Baseline clinical, hormonal and molecular markers associated with clinical response to IL-23 antagonism in hidradenitis suppurativa: A prospective cohort study', Experimental Dermatology, 32, pp. 869 - 877, http://dx.doi.org/10.1111/exd.14789
,2023, 'Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study', JAAD International, 11, pp. 143 - 144, http://dx.doi.org/10.1016/j.jdin.2023.02.006
,2023, 'Academic dermatology in Australia and New Zealand between 2017 and 2022: A cross-sectional bibliometric analysis', Australasian Journal of Dermatology, 64, pp. 213 - 220, http://dx.doi.org/10.1111/ajd.14025
,2023, 'In search of therapeutic biomarkers to interleukin-23 antagonism in hidradenitis suppurativa', British Journal of Dermatology, 188, pp. 588 - 589, http://dx.doi.org/10.1093/bjd/ljad027
,2023, 'Angiotensin-converting enzyme 2 expression is elevated in tissue of hidradenitis suppurativa and pyoderma gangrenousm and demonstrates a different pattern of expression to psoriasis vulgaris', Journal of the European Academy of Dermatology and Venereology, 37, pp. e372 - e374, http://dx.doi.org/10.1111/jdv.18543
,2023, 'Monkeypox: Cutaneous clues to clinical diagnosis', Journal of the American Academy of Dermatology, 88, pp. 698 - 700, http://dx.doi.org/10.1016/j.jaad.2022.08.048
,2023, 'Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility', British Journal of Dermatology, 188, pp. 294 - 295, http://dx.doi.org/10.1093/bjd/ljac060
,2023, 'Dupilumab-associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia-specific immunoglobulin E levels mirroring clinical response', Journal of the American Academy of Dermatology, 88, pp. 255 - 257, http://dx.doi.org/10.1016/j.jaad.2022.05.021
,2023, '1323 Human dermal fibroblasts and mast cell populations are altered in hidradenitis suppurativa, with epithelial-mesenchymal-transition signals ameliorated by spleen tyrosine kinase antagonism.', Journal of Investigative Dermatology, 143, pp. S227 - S227, http://dx.doi.org/10.1016/j.jid.2023.03.1339
,2023, 'LB1700 SYK antagonism in hidradenitis suppurativa demonstrates clinical efficacy with grearter response in B-cell predominant disease: Results of a open-label, proof-of-concept phase 2 clinical trial', Journal of Investigative Dermatology, 143, pp. B15 - B15, http://dx.doi.org/10.1016/j.jid.2023.06.074
,2022, 'Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa', Experimental Dermatology, 31, pp. 1872 - 1880, http://dx.doi.org/10.1111/exd.14665
,2022, 'Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study', Journal of the American Academy of Dermatology, 87, pp. 1440 - 1442, http://dx.doi.org/10.1016/j.jaad.2022.07.047
,2022, 'Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects', International Journal of Dermatology, 61, pp. 1175 - 1186, http://dx.doi.org/10.1111/ijd.15910
,2022, 'The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study*', British Journal of Dermatology, 187, pp. 523 - 530, http://dx.doi.org/10.1111/bjd.21673
,2022, 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?', Clinical and Experimental Dermatology, 47, pp. 1585 - 1586, http://dx.doi.org/10.1111/ced.15232
,2022, 'Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum', British Journal of Dermatology, 187, pp. 223 - 233, http://dx.doi.org/10.1111/bjd.21060
,2022, 'Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls', Journal of the European Academy of Dermatology and Venereology, 36, pp. e580 - e583, http://dx.doi.org/10.1111/jdv.18075
,2022, 'Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts', Skin Appendage Disorders, 8, pp. 287 - 290, http://dx.doi.org/10.1159/000521268
,2022, 'A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality', JAAD Case Reports, 24, pp. 82 - 87, http://dx.doi.org/10.1016/j.jdcr.2022.04.019
,2022, 'Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study', British Journal of Dermatology, 186, pp. 1050 - 1052, http://dx.doi.org/10.1111/bjd.21019
,2022, 'Extramammary Paget's disease Harbinger of internal malignancy', Australian Journal of General Practice, 51, pp. 351 - 352, http://dx.doi.org/10.31128/AJGP-05-21-5981
,2022, 'Large-scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*', British Journal of Dermatology, 186, pp. 684 - 693, http://dx.doi.org/10.1111/bjd.20642
,2022, 'Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease', Experimental Dermatology, 31, pp. 498 - 515, http://dx.doi.org/10.1111/exd.14534
,2022, 'Autoantibody-Mediated Macrophage Responses Provide the Missing Link between Innate and Adaptive Immune Dysfunction in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 142, pp. 747 - 749, http://dx.doi.org/10.1016/j.jid.2021.08.400
,2022, 'Dermatology and wound research: Targeting inflammation through cooperation and collaboration', Wound Practice and Research, 30, pp. 5, http://dx.doi.org/10.33235/wpr.30.1.5
,2022, 'Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review', JAMA Dermatology, 158, pp. 300 - 313, http://dx.doi.org/10.1001/jamadermatol.2021.4926
,2022, 'Antimicrobial peptides in hidradenitis suppurativa: a systematic review*', British Journal of Dermatology, 186, pp. 236 - 244, http://dx.doi.org/10.1111/bjd.20750
,2022, 'The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris', Journal of the American Academy of Dermatology, 86, pp. 322 - 330, http://dx.doi.org/10.1016/j.jaad.2021.07.035
,2022, 'Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry', Journal of the American Academy of Dermatology, 86, pp. 249 - 252, http://dx.doi.org/10.1016/j.jaad.2021.09.016
,2022, 'Cutaneous infection and atopic dermatitis: the importance of early intervention in Indigenous children in Australia', Wound Practice and Research, 30, pp. 34 - 39, http://dx.doi.org/10.33235/wpr.30.1.34-39
,2022, 'High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression', Journal of Allergy and Clinical Immunology, 149, pp. 135 - 144.e12, http://dx.doi.org/10.1016/j.jaci.2021.05.027
,2022, 'Pathergy: a review of potential mechanisms and novel therapeutic targets', Wound Practice and Research, 30, pp. 55 - 61, http://dx.doi.org/10.33235/wpr.30.1.55-61
,2022, 'Pyoderma gangrenosum: a review of the clinical, mechanistic and therapeutic landscape', Wound Practice and Research, 30, pp. 16 - 23, http://dx.doi.org/10.33235/wpr.30.1.16-23
,2022, 'The pathogenesis of hidradenitis suppurativa: Evolving paradigms in a complex disease', Dermatological Reviews, 3, pp. 39 - 49, http://dx.doi.org/10.1002/der2.113
,2021, 'Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa', Journal of the European Academy of Dermatology and Venereology, 35, pp. e884 - e887, http://dx.doi.org/10.1111/jdv.17536
,2021, 'Cellular neurothekeoma', International Journal of Women's Dermatology, 7, pp. 835 - 837, http://dx.doi.org/10.1016/j.ijwd.2021.07.011
,2021, 'Clinical considerations in the management of hidradenitis suppurativa in women[Formula presented]', International Journal of Women's Dermatology, 7, pp. 664 - 671, http://dx.doi.org/10.1016/j.ijwd.2021.10.012
,2021, 'A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa', Experimental Dermatology, 30, pp. 1388 - 1397, http://dx.doi.org/10.1111/exd.14141
,2021, 'A systematic review of reported cases of pachyonychia congenita tarda (vol 44, pg 606, 2019)', CLINICAL AND EXPERIMENTAL DERMATOLOGY, 46, pp. 1395 - 1395, http://dx.doi.org/10.1111/ced.14864
,2021, 'An Abscess Is Not a Descriptive Term but an Entity with a Universally Accepted Definition - A Clarification on Semantics - Reply', JAMA Dermatology, 157, pp. 1245 - 1246, http://dx.doi.org/10.1001/jamadermatol.2021.2495
,2021, 'Therapeutic biomarkers in hidradenitis suppurativa: one step closer to the clinic', British Journal of Dermatology, 185, pp. 696 - 697, http://dx.doi.org/10.1111/bjd.20513
,2021, 'Differential profiles of gamma secretase Notch signalling in hidradenitis suppurativa: the need for genotype–endotype–phenotype analysis', British Journal of Dermatology, 185, pp. 636 - 637, http://dx.doi.org/10.1111/bjd.19805
,2021, 'In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes', Journal of Investigative Dermatology, 141, pp. 2197 - 2207, http://dx.doi.org/10.1016/j.jid.2021.02.742
,2021, 'Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)', JAAD Case Reports, 14, pp. 33 - 36, http://dx.doi.org/10.1016/j.jdcr.2021.05.029
,2021, 'Ultrasound-guided de-roofing of epithelialised tunnels of hidradenitis suppurativa', Australasian Journal of Dermatology, 62, pp. 360 - 363, http://dx.doi.org/10.1111/ajd.13600
,2021, 'The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa', Frontiers in Medicine, 8, http://dx.doi.org/10.3389/fmed.2021.603281
,